A detailed history of Gf Fund Management Co. Ltd. transactions in Avidity Biosciences, Inc. stock. As of the latest transaction made, Gf Fund Management Co. Ltd. holds 2,961 shares of RNA stock, worth $209,638. This represents 0.0% of its overall portfolio holdings.

Number of Shares
2,961
Previous 2,768 6.97%
Holding current value
$209,638
Previous $121 Million 77.09%
% of portfolio
0.0%
Previous 0.0%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2025

Jan 26, 2026

BUY
$43.0 - $70.84 $8,299 - $13,672
193 Added 6.97%
2,961 $214 Million
Q3 2025

Nov 06, 2025

SELL
$28.46 - $50.36 $8,168 - $14,453
-287 Reduced 9.39%
2,768 $121 Million
Q1 2025

Apr 28, 2025

BUY
$27.05 - $35.11 $14,877 - $19,310
550 Added 21.96%
3,055 $90.2 Million
Q4 2024

Feb 18, 2025

BUY
$29.08 - $52.5 $72,845 - $131,512
2,505 New
2,505 $72.8 Million

Others Institutions Holding RNA

About Avidity Biosciences, Inc.


  • Ticker RNA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 52,127,000
  • Market Cap $3.69B
  • Description
  • Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic...
More about RNA
Track This Portfolio

Track Gf Fund Management Co. Ltd. Portfolio

Follow Gf Fund Management Co. Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Gf Fund Management Co. Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Gf Fund Management Co. Ltd. with notifications on news.